Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Gene Expression Assays

May 16, 2011 11:22 am | Product Releases | Comments

Fluidigm Corporation announced the availability of the DELTAgene Assays (gene expression), SNPtype Assays (SNP genotyping), and Access Array Target-specific Primers (target enrichment for next-generation sequencing).

TOPICS:

Ultrasonic Coating System

May 16, 2011 11:16 am | Product Releases | Comments

The ExactaCoat XYZ motion ultrasonic coating system from Sono-Tek Corporation is ideal for spraying medical device components such as pacemakers, diagnostic leads, or any small medical device requiring targeted coating of anti-microbials or other solutions.

TOPICS:

arGEN-X Moves ARGX-110 Forward in Development

May 16, 2011 11:07 am | News | Comments

arGEN-X announces that it has progressed ARGX-110, its second therapeutic candidate, into formal pre-clinical development. ARGX-110 has potential to improve treatment of autoimmune disorders, inflammation, and cancer.

TOPICS:
Advertisement

Otsuka Depression Trial Meets Primary Endpoint

May 16, 2011 11:02 am | News | Comments

Otsuka Pharmaceutical Co., Ltd. announced that a Phase 2 trial of OPC-34712, showed that patients demonstrated improvement in the Montgomery Åsberg Depression Rating Scale Total Score.

TOPICS:

FDA Gives Nod to Perrigo Generic

May 16, 2011 10:55 am | News | Comments

Perrigo Company announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for over-the-counter Ranitidine 150, a generic version of Zantac 150.

TOPICS:

PerkinElmer Buys Labtronics

May 16, 2011 10:53 am | News | Comments

PerkinElmer, Inc. announced that it has acquired Labtronics Inc., an leader in providing procedures-based electronic laboratory notebook solutions for laboratories performing routine analysis in multiple industries.

TOPICS:

Merck Wraps Up Inspire Acquisition

May 16, 2011 10:44 am | News | Comments

Merck & Co. said it completed its $430 million purchase of eye-drug maker Inspire Pharmaceuticals Inc. In the deal, Merck gets Inspire's drug Azasite, which is used to treat pink eye caused by bacteria.

TOPICS:

Mylan Selling Generic Xibrom

May 16, 2011 10:40 am | News | Comments

Mylan Inc. said it is now selling a generic version of Xibrom eye drops, which were discontinued in February by their original maker, ISTA Pharmaceuticals Inc.

TOPICS:
Advertisement

Teva Buys $460M Stake in Taiyo

May 16, 2011 10:39 am | News | Comments

Teva Pharmaceutical Industries Ltd. said it will pay $460 million to acquire a majority stake in Japanese generic drugmaker Taiyo Pharmaceutical Industry Co., and said it expects its annual sales in Japan to reach $1 billion in the next few years.

TOPICS:

Amylin Suing Lilly Over Broken Deal

May 16, 2011 10:36 am | by Tom Murphy | News | Comments

Amylin Pharmaceuticals Inc. filed a lawsuit against Eli Lilly and Co., accusing the larger drugmaker of breaking their commercialization deal for diabetes drugs by teaming with Boehringer Ingelheim to develop and sell a competing product.

TOPICS:

Leukemia Society Supports Multiple Myeloma Trial

May 16, 2011 8:32 am | News | Comments

The Leukemia & Lymphoma Society (LLS) and Acetylon Pharmaceuticals announced a business alliance to jointly support a Phase I/II clinical trial of Acetylon’s HDAC6 inhibitor drug candidate, ACY-1215, in multiple myeloma.

TOPICS:

Astellas Pharma, BioFocus Collaborate on CNS Target Discovery

May 16, 2011 8:23 am | News | Comments

BioFocus has signed a collaboration agreement with Astellas Pharma Inc. focused on discovering novel targets in the field of CNS disorders.

TOPICS:

New Class of Compounds Block Serine Hydrolases

May 16, 2011 8:17 am | News | Comments

Scientists from The Scripps Research Institute have identified a class of compounds that powerfully and selectively block the activity of a large and diverse group of enzymes known as serine hydrolases.. Previously discovered serine hydrolase-blocking compounds have been turned into drugs to treat obesity, diabetes, and Alzheimer’s disease, and are currently in testing as treatments for pain, anxiety, and depression.

TOPICS:

Anti-flu virus Proteins Designed via Computational Methods

May 16, 2011 8:10 am | News | Comments

Researchers at the University of Washington have demonstrated the use of computational methods to design new antiviral proteins capable of targeting specific surfaces of flu virus molecules.

TOPICS:

Teijin Pharma to Launch Feburic

May 16, 2011 7:51 am | News | Comments

Teijin Pharma Limited will launch Feburic (febuxostat, TMX-67), for treating hyperuricemia in Japan on May 17.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading